Skip to Content

Generic Troxyca ER Availability

Troxyca ER is a brand name of naltrexone/oxycodone, approved by the FDA in the following formulation(s):

TROXYCA ER (naltrexone hydrochloride; oxycodone hydrochloride - capsule, extended release;oral)

  • Manufacturer: PFIZER INC
    Approval date: August 19, 2016
    Strength(s): 1.2MG;10MG, 2.4MG;20MG, 3.6MG;30MG, 4.8MG;40MG, 7.2MG;60MG, 9.6MG;80MG

Has a generic version of Troxyca ER been approved?

No. There is currently no therapeutically equivalent version of Troxyca ER available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Troxyca ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Sequestering subunit and related compositions and methods
    Patent 7,815,934
    Issued: October 19, 2010
    Inventor(s): Boehm; Garth
    Assignee(s): Alpharma Pharmaceuticals, LLC
    A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit and a therapeutic agent in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.
    Patent expiration dates:
    • December 12, 2027
      ✓ 
      Drug product
  • Sequestering subunit and related compositions and methods
    Patent 8,685,443
    Issued: April 1, 2014
    Assignee(s): Alpharma Pharmaceuticals LLC
    A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.
    Patent expiration dates:
    • July 3, 2025
      ✓ 
      Patent use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • August 19, 2019 - NEW COMBINATION

More about Troxyca ER (naltrexone / oxycodone)

Consumer resources

Professional resources

Related treatment guides

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
Hide